학술논문

Risk prediction for local versus regional/metastatic tumors after initial ductal carcinoma in situ diagnosis treated by lumpectomy.
Document Type
article
Source
Breast cancer research and treatment. 157(2)
Subject
Humans
Carcinoma
Intraductal
Noninfiltrating
Breast Neoplasms
Neoplasm Metastasis
Mammography
Prognosis
Treatment Outcome
Mastectomy
Segmental
Risk Factors
Survival Analysis
Retrospective Studies
Adult
Aged
Middle Aged
Female
Young Adult
Biomarkers
Tumor
Ductal carcinoma in situ
Local invasive cancer
Recurrence
Regional/metastatic invasive cancer
Risk
Carcinoma
Intraductal
Noninfiltrating
Mastectomy
Segmental
Biomarkers
Tumor
Cancer
Prevention
Clinical Research
4.2 Evaluation of markers and technologies
Oncology & Carcinogenesis
Oncology and Carcinogenesis
Clinical Sciences
Language
Abstract
Among women diagnosed with ductal carcinoma in situ (DCIS), we identified factors associated with local invasive cancer (LIC) and regional/metastatic invasive cancer (RMIC) and provide 10-year risks based on clinically relevant factors. We created a retrospective, population-based cohort of 1492 women with an initial diagnosis of DCIS (1983-1996) treated by lumpectomy alone. Histological and molecular markers (Ki67, ER, PR, COX-2, p16, ERBB2) were collected on DCIS cases with a subsequent tumor (DCIS, LIC, or RMIC) and a subsample of frequency-matched controls without subsequent tumors. Competing risks methods were used to identify factors associated with LIC and RMIC and cumulative incidence methods to estimate 10-year risks for combinations of factors. Median follow-up time was 12.6 years (range 0.5-29.5 years). The overall 10-year risk of LIC (11.9 %) was higher than for RMIC (3.8 %). About half of women with initial DCIS lesions are detected by mammography and p16 negative and have a 10-year risk of LIC of 6.2 % (95 % CI 5.8-6.8 %) and RMIC of 1.2 % (95 % CI 1.1-1.3 %). Premenopausal women whose DCIS lesion was p16 positive or p16 negative and detected by palpation had high 10-year risk of LIC of 23.0 % (95 % CI 19.3-27.4 %). Ten-year risk of RMIC was highest at 22.5 % (95 % CI 13.8-48.1 %) for those positive for p16, COX-2, and ERRB2, and negative for ER, but prevalence of this group is low at 3 %. Ten-year risk of LIC and RMIC is low for the majority diagnosed with DCIS. Combinations of molecular markers and method of detection of initial DCIS lesion can differentiate women at low and high risk of LIC and RMIC.